Novavax’s COVID-19 vaccine received emergency use authorization Tuesday from the U.S. Food and Drug Administration (FDA) and can be used to immunize people 12 years and older.
The vaccine now is included in the recommendations from the U.S. Centers for Disease Control and Prevention (CDC).
The company, which is located in Gaithersburg, expects to make its doses available nationwide at retail pharmacies and physicians’ offices once the Center for Biologics Evaluation and Research release the batches.
“COVID-19 is once again on the rise with infections and hospitalizations increasing, so it’s important that individuals get vaccinated to protect themselves and their loved ones,” said John C. Jacobs, Novavax president and CEO.
“Novavax’s authorization today means people will now have the choice of a protein-based non-MRNA option to help protect themselves against COVID-19, which is now the fourth leading cause of death in the U.S. In the coming days, individuals in the U.S. can go to pharmacies, physicians’ offices, clinics and various government entities to receive an updated Novavax vaccine,” he wrote in a news release.
In clinical trials, the most common adverse reactions associated with Novavax’s prototype COVID-19 vaccine (NVX-CoV2373) included headache, nausea or vomiting, muscle pain, joint pain, injection site tenderness, injection site pain, fatigue and malaise, according to the news release.
Novavax COVID-19 vaccine has not been approved or licensed by the FDA but has been authorized for emergency use by that federal body.
The U.S. FDA has granted Emergency Use Authorization for Novavax’s COVID-19 vaccine, Adjuvanted (2023-2024 Formula) to prevent COVID-19 in individuals aged 12 and older. pic.twitter.com/OsPF0aauPx
— Novavax (@Novavax) October 3, 2023
Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
Read more: https://t.co/kqvAbYrdEC pic.twitter.com/mswDWO0STK
— Novavax (@Novavax) October 3, 2023
Related Post
